Introduction
Among the most intriguing discoveries in developmental biology in the last century has been the identification of powerful developmentally regulated transcription factors that regulate patterning and cell-fate determination during embryogenesis. Expression of myogenic basic helix-loop-helix transcription factors, for example, is required for skeletal muscle differentiation and can induce myogenic differentiation in naive cells (1) (2) (3) (4) . Homeobox genes specify anterior-posterior identity and are frequently required for patterning and differentiation of organs and tissues throughout the body (5) . Gene inactivation studies in mice and other organisms have verified the critical role played by innumerable transcriptional regulators during embryogenesis. Many of these factors are silenced or inactivated during embryonic development as differentiation proceeds, yet few studies have addressed the importance of this aspect of gene regulation. Is inactivation of specific developmental transcription factors required for differentiation and patterning to occur normally? Is turning off a gene just as important as turning it on? We sought to address these questions using an in vivo approach in mice.
Paired box 3 (Pax3) is a developmentally regulated transcription factor that is expressed in neural crest and somitic mesoderm (6) and is implicated in neural crest disorders, including the Splotch phenotype in mice and Waardenburg syndrome in humans. Pax3 is required for neural crest development and differentiation, since mutations in Pax3 result in a wide variety of neural crest defects, including small or absent dorsal root ganglia, melanocyte defects, and congenital heart disease related to deficient septation and smooth muscle development in the outflow tract of the heart (7, 8) . In the skin, Pax3 expression abates during melanocyte differentiation of neural crest derivatives, but expression persists in a small population of undifferentiated melanocyte precursors, suggesting a role in stem cell biology (9) . Pax3 is also required for some aspects of skeletal muscle development, where it is thought to act upstream of MyoD (10) , and Pax3 is expressed by undifferentiated satellite cells, which can function as skeletal muscle stem cells (11, 12) . Expression of a Pax3-forkhead (FKHR) fusion protein results in tumors of skeletal muscle in humans (rhabdomyosarcoma), and Pax3 itself is overexpressed in many cases of rhabdomyosarcoma that are not associated with the Pax3-FKHR translocation (13, 14) .
Pax3 is a member of the paired-box family of transcription factors, which includes 9 members in mice and humans (7) . Each member of the family is expressed in a tissue-specific pattern during development, and as in the case of Pax3, expression generally abates upon differentiation. In the eye, Pax6 plays a vital role since mutations in flies, mice, and humans result in severe ocular malformations or complete absence of the eye (15) . Pax6 is required in retinal progenitor cells to maintain multipotency (16) , and the persistence of Pax6-expressing cells in the adult eye in some lower organisms is associated with the ability to regenerate the eye upon injury (17, 18) . In the hematopoietic system, Pax5 is expressed by pre-B cells and expression abates during further differentiation, while persistent expression is associated with some leukemias (19) .
We have previously shown that Pax3 plays a cell-autonomous role in neural crest development, since transgenic rescue of Pax3 expression in neural crest is sufficient to rescue development and survival in a Pax3-null mouse (20) . Direct transcriptional targets of Pax3 in neural crest are generally unknown, though it may regulate the cell-surface tyrosine kinase receptor c-ret in enteric ganglia precursors (21) and Mitf in melanoblasts (22, 23) . Microarray analysis and chromatin immunoprecipitation studies have identified a number of other potential targets including TGF-β2 (24) . A wide variety of neural crest defects have been associated with Pax3 deficiency, though some aspects of neural crest development are thought to be preserved in Pax3 mutants because of redundant functions of the closely related Pax7 gene, which is frequently coexpressed (25) . Hence, Pax3/Pax7 double mutants have a more severe phenotype than either mutant alone. During development in the mouse, Pax3 expression initiates in the dorsal neural tube at about E8.0 followed shortly by expression of Pax7. By E10.5-E11, Pax3 expression is extinguished in neural crest cells as they migrate away from the neural tube, though expression by neuroblasts within the dorsal neural tube more gradually diminishes through gestation. In cranial regions, Pax3-expressing neural crest cells compose the mesenchymal cells of the maxillary and mandibular regions forming bone and muscle and contribute to the developing eyelids and periocular tissues.
Here, we describe studies that test the requirement for Pax3 to be inactivated during embryonic development. Using gene targeting and Cre-lox approaches, we have engineered mice in which Pax3 is activated normally during development, but expression persists beyond the time points at which it is normally shut off. This results in perinatal lethality, cleft palate, and additional defects. Further, using a combination of microarray and bioinformatics applications, we have identified what we believe is a novel downstream target of Pax3 regulation, the secreted bone morphogenetic protein (BMP) inhibitor sclerostin domain-containing 1 (Sostdc1). Persistent Pax3-mediated upregulation of Sostdc1 results in delayed osteogenesis, accounting for the lethal cleft palate phenotype. Thus, our results demonstrate the importance of gene inactivation during development. 
Results
Targeting a Cre-inducible Pax3 cDNA to the Rosa locus. The Rosa (Gt(ROSA)26Sor) locus had been successfully utilized to mediate widespread expression in the mouse embryo (26) . We utilized a strategy designed to introduce the Pax3 cDNA into the Rosa locus immediately downstream of a loxP-flanked PGK-neo cassette that included stop codons in all 3 reading frames ( Figure 1A ). Thus, Pax3 would not be expressed unless Cre-mediated recombination removed the PGK-neo cassette, bringing Pax3 under the control of the Rosa locus regulatory elements. ES cells were targeted, and appropriate integration was confirmed by Southern blot ( Figure  1B ). Targeted (129X1/SvJ × 129S1/Sv) F1-derived R1 ES cells were capable of expressing Pax3 after infection with adenovirus encoding Cre recombinase ( Figure 1 , C and D), confirming appropriate targeting and Cre-mediated regulation. Correctly targeted ES cells were microinjected in C57BL/6 blastocysts, and chimeric progeny were established. After breeding to C57BL/6 mice, resulting heterozygotes were named R26 Pax3/+ mice and subsequently derived homozygotes were named R26 Pax3/Pax3 mice. Both heterozygotes and homozygotes appeared normal and were able to breed and thrive.
Persistent expression of Pax3 in Pax3-expressing cells. In order to activate Pax3 expression specifically in Pax3-expressing cells, we bred R26 Pax3/+ mice with animals in which Cre recombinase had been targeted to the endogenous Pax3 locus (Pax3 Cre/+ mice). Pax3 Cre/+ mice have been previously described (27) During embryogenesis, Pax3 expression initiates at approximately E8.0 in the dorsal neural tube and subsequently appears in presomitic mesoderm (6) . Pax3 expression in noncranial neural crest normally abates shortly after delamination of neural crest cells from the neural tube, while expression persists slightly longer in cranial crest derivatives. By late gestation, the majority of Pax3 expression has disappeared, though expression in some Schwann cells (28) and satellite cells in muscle (12) persists into adulthood. Pax3 is required for subsets of neural crest and skeletal muscle development, and Pax3-deficient Splotch mutants display neural tube defects, deficiencies of neural crest, including congenital heart disease, and deficiencies of limb and other hypaxial muscles (7) . By E13.5, neural crest-derived smooth muscle cells in the aortic arch did not express Pax3 protein ( Figure 1E ). However, in Pax3 Cre/+ , R26 Pax3/+ embryos, Pax3 is easily detected in the smooth muscle layer of the aortic arch at E16.5 (not shown), and even higher levels of Pax3 expression are evident in Pax3 Cre/+ , R26 Pax3/Pax3 embryos that carry 2 copies of the R26Pax3 allele ( Figure 1E ). Similar findings were observed in other Pax3-derived cell types, including dorsal neural tube, adrenal medulla, and skeletal muscle (data not shown). These results demonstrate that persistent Pax3 expression was effectively engineered in Pax3 derivatives.
At E11.5, we identified embryos of each of the expected genotypes (Supplemental Table 1 Figure  1F ). Thus, persistent expression of Pax3 from the Rosa26 locus achieves levels comparable to those produced from the wild-type Pax3 locus at mid-gestation.
Rescue of developmental defects. We have previously reported that Pax3 Cre/Cre mice display neural tube and skeletal muscle defects sim- ilar to those seen in Pax3-deficient Splotch mice (27) . We predicted that, if Pax3 protein expressed from the Cre-activated R26 Pax3 allele was functional, this expression would be sufficient to rescue developmental defects in mice that lacked Pax3 derived from the endogenous locus. Pax3 Cre/Cre , R26 +/+ E13.5 embryos derived from intercrosses of Pax3 Cre/+ , R26 Pax3/+ mice always displayed neural tube defects, either in the lumbar or cranial regions or both (Figure 2A) . However, Pax3 Cre/Cre embryos that also carried 1 or 2 alleles of R26 Pax3 never displayed neural tube defects, indicating that Cre-dependent Pax3 expression from the Rosa locus was sufficient to rescue neural tube closure in embryos lacking Pax3 expression from the endogenous locus. Cre-mediated expression of Pax3 from the Rosa locus was also sufficient to rescue muscular development of the diaphragm ( Figure 2B ) and hind limb (Supplemental Figure 1) , which is deficient in Pax3 Cre/Cre embryos. However, we did not observe complete rescue of all hypaxial muscles in R26 Pax3/Pax3 , Pax3 Cre/Cre embryos, since forelimb musculature remained hypoplastic (Supplemental Figure 1) , perhaps because Cre-mediated activation of Pax3 expression from the Rosa locus was slightly delayed when compared with the onset of endogenous Pax3 expression in wild-type embryos. We conclude that expression from the Rosa locus in the manner described was able to rescue most, but not all, developmental functions of Pax3.
Cleft palate in mice persistently expressing Pax3. Although Pax3 Cre/+ , R26 Pax3/+ mice survived, we never observed Pax3 Cre/+ , R26 Pax3/Pax3 mice beyond P2 (Supplemental Table 1 Figure 2 ). Quail-chick chimera experiments have demonstrated that neural crest cells migrate to and intermingle with mesodermal cells to contribute to both upper and lower eyelid development (34) .
We sought to confirm these results by performing an independent experiment in which persistent Pax3 expression was activated using a transgenic mouse with well-characterized expression of Cre recombinase that is limited to neural crest (29, 35) . Using Wnt1-Cre-driven persistent expression of Pax3, we observed identical morphological defects involving the palate, eyelids, and cranial bones in Wnt1Cre, R26 Pax3/Pax3 mice compared with Pax3 Cre/+ , R26 Pax3/Pax3 , and all 15 Wnt1Cre, R26 Pax3/Pax3 mice examined were abnormal. We also Persistent Pax3 expression impairs osteogenic differentiation. In order to determine whether the cleft palate was due to an osteogenic defect, we examined palate mineralization at critical developmental time points. At E15.5, palatal shelves have normally lifted and fused at the midline, with epithelial to mesenchymal transition occurring at the fusion seam. By E15.5, mineralization at the periphery of the palate is normally visible ( Figure 5A ). Goldner's trichromestained sections through the palates of E15.5 and E17.5 Pax3 Cre/+ , R26 Pax3/Pax3 embryos revealed a distinct decrease in mineralization compared with control, with an absence of mineralization of the ossifying centers at the midline at E17.5 ( Figure 5A ). This decrease in mineralization was also evident at embryonic E14.5 and E16.5 (data not shown).
The decrease in palate mineralization suggested a defect in osteoblastogenesis. We isolated primary palate mesenchymal cells from E14.5 embryos and cultured them in the presence or absence of BMP-2 to determine their osteogenic potential. Primary palate cultures from control mice were able to form nodules and mineralize ex vivo, as shown by Von Kossa staining, when treated with BMP-2 ( Figure 5B ) but not in the absence of BMP-2 (data not shown). In contrast, BMP-treated primary palate cultures that persistently expressed Pax3 failed to form nodules and mineralize ( Figure 5B ). In order to determine whether the cause of the block in mineralization was due to a defect in osteoblast differentiation, we examined the expression of alkaline phosphatase (ALP), an early marker of osteoblastogenesis. Similar to our mineralization results, primary palate cultures from control mice responded robustly to BMP-2 treatment with high levels of ALP expression. However, palate cultures persistently expressing Pax3 failed to increase ALP levels in response to BMP-2 treatment ( Figure 5C ). Persistent expression of Pax3 in the primary palate cultures was confirmed by immunofluorescence ( Figure 5D ). Nearly all cells isolated in the primary palate cell preparation were positive for Pax3, indicating that the primary cultures were primarily mesenchymal cells derived from cranial neural crest of the Pax3-expressing linage. In contrast, cells isolated from control mice had no detectable Pax3, consistent with the previously observed downregulation of endog- Pax3-expressing cranial crest is resistant to BMP-induced signaling. Despite abundant BMP expression in cranial regions, cranial crest normally fails to exhibit signs of osteogenic differentiation until Pax3 expression abates. Persistent expression of Pax3 further delays and impairs osteogenesis. Thus, we examined the effect of persistent Pax3 expression on early markers of BMP signaling and downstream targets. Runx2, a runt-domain transcription factor often described as the master regulator of osteoblast commitment and differentiation, is required for bone development (36) (37) (38) (39) (40) (41) (42) and functions downstream of BMPs (43, 44) . Runx2-null mice die postnatally with respiratory failure due to a complete lack of mineralized bone (38) . Overexpression of Runx2 in mesenchymal cell lines induces the expression of bone cell markers such as collagen type 1, ALP, and osterix, an osteoblast-specific protein (36, Figure 6B ). Immunohistochemical analysis of E12.5, E13.5, and E14.5 palates using anti-Runx2 antibody staining confirmed the decrease in Runx2 levels in the palate, which was more pronounced at E13.5 and E14.5, when endogenous Pax3 levels were decreased ( Figure 6B ). The decrease in Runx2 expression was more pronounced in posterior areas of the developing palate (Supplemental Figure 3) , consistent with our observation that the most penetrant aspects of the cleft palate phenotype are found in posterior regions. Similar observations of regional heterogeneity of gene expression in the developing palate have been described previously (46) .
Resistance to BMP signaling would be expected to be associated with diminished activation of downstream components of the pathway, such as phosphorylation of the BMP-dependent Smads 1, 5, and 8. During normal palate development, phosphorylated Smad1/5/8 is first detected at approximately E13.5, coincident with downregulation of Pax3, and this is followed shortly thereafter by activation of Runx2 expression and osteogenic differentiation (data not shown). Immunohistological examination of sectioned E15.5 palatal shelves reveals a marked decrease of phosphorylated Smad1/5/8 in the regions of defective osteoblast differentiation and mineralization in the Pax3 Cre/+ , R26 Pax3/Pax3 embryos compared with wild-type littermates ( Figure 6C ). 
Upregulation of Sostdc1, an inhibitor of BMP signaling.
The data summarized above are consistent with diminished BMP responsiveness in cranial crest cells that express Pax3. We sought to identify the mechanism responsible for relative resistance of Pax3-expressing mesenchyme to BMP-mediated signals. Quantitative RT-PCR analysis (not shown) and in situ expression analysis of candidate components of the BMP signaling pathway, including both type 1 BMP receptors (BMPR-1a and BMPR-1b) and BMP-2, failed to reveal significant changes in Pax3 Cre/+ , R26 Pax3/Pax3 embryos compared with controls (Supplemental Figure 4) . However, microarray analysis of RNA isolated from dissected E14.5 palatal shelves of Pax3 Cre/+ , R26 Pax3/Pax3 and control littermate embryos revealed a nearly 2-fold increase in expression of the secreted BMP inhibitor Sostdc1, also known as Ectodin. This was confirmed by QPCR, which revealed a 1.5-fold increase ( Figure 6D) . Furthermore, QPCR analysis of RNA from day 1, 3, and 6 primary palate cultures revealed a progressive increase in Sostdc1 produced by cells persistently expressing Pax3 when compared with controls ( Figure 6E ), while expression of the other BMP inhibitors Noggin, Tob, and Gremlin was not significantly altered (data not shown).
Reanalysis of our microarray data using modified bioinformatics algorithms was performed to identify potential regulatory elements found more commonly in up-or downregulated genes than in those that are unchanged. We evaluated 5 kb of genomic sequence upstream of the coding regions of the top 50 up-or downregulated genes and searched for any 10-bp nucleotide motifs that were overrepresented within noncoding genomic regions that were conserved between mouse and human sequences using the PhyME 1.2 program. We identified a motif with the consensus sequence AAAGACAGAA that occurred at a statistically significant higher frequency in regulated gene sequences than was predicted by chance; this sequence achieved the highest computational composite score according to an a priori weighting strategy. Interestingly, this consensus bears resemblance to the optimal Pax3 paireddomain-binding site previously described (5 of 9 bp matches; ref. 47) . The highest scoring differentially regulated gene identified by this approach was Sostdc1, which contains at least 2 consensus sites within the 5-kb upstream region (-590 and -3075).
We empirically tested for Pax3 binding to the consensus Sostdc1 promoter motifs by electrophoretic mobility shift assays. Incubation of increasing amounts of nuclear extracts from Pax3-transfected 293T cells resulted in increasing amounts of bound (shifted) probe for both the proximal (-590) and distal (-3075) motifs, although significantly more extract was required to shift the distal motif probe ( Figure 7A ), suggesting lower affinity. Unlabeled proximal (-590) motif DNA effectively competes for binding, and unlabeled competitor DNA containing a previously validated Pax3 paired-domain-binding site (48) was somewhat more effective in competition assays than the -590 probe itself. A mutated proximal motif in which 4 residues within the binding element are altered is unable to effectively compete with labeled probe for binding to Pax3 ( Figure 7B ).
Pax3 can also interact with the Sostdc1 upstream genomic region as determined by ChIP assays. ChIP analysis demonstrates that Pax3 interacts with Sostdc1 promoter fragments that contain either the proximal (-590) motif or the distal (-3075) motif ( Figure 7C ). Control experiments with nonspecific IgG1 immunoglobulin do not precipitate these fragments, and control DNA fragments are not precipitated with the Pax3-specific antibody, demonstrating the specificity of the interaction ( Figure 7C ).
These results suggested that Pax3 could regulate expression of Sostdc1 in cranial mesenchyme. Hence, we asked whether this mechanism could account for BMP resistance and osteogenic defects identified in Pax3 Cre/+ , R26 Pax3/Pax3 mice. BMP-2 induces phosphorylation of Smad1/5/8 in wild-type primary palate cultures; however, palate cultures persistently expressing Pax3 show impaired Smad1/5/8 phosphorylation in response to BMP-2 ( Figure 7D ). Importantly, conditioned medium harvested from the cultures persistently expressing Pax3 is sufficient to mimic the blunted response to BMP-2 treatment in control cells, suggesting that a secreted factor from the Pax3 Cre/+ , R26 Pax3/Pax3 cells is indeed responsible for this effect ( Figure 7D ). Conditioned medium from wild-type cultures did not display this activity. Wild-type primary palate cultures treated with conditioned medium from 293T cells transfected with myc-tagged Sostdc1 show a similar blunted response of Smad1/5/8 phosphorylation in response to BMP-2. This effect was not seen when cells were treated with conditioned medium from control-transfected cells ( Figure 7E ). Thus, we conclude that sustained expression of Pax3 in neural crest-derived palatal mesenchyme results in decreased BMP signaling and Smad activation associated with increased levels of the secreted BMP inhibitor Sostdc1 as well as defective osteogenic differentiation.
Discussion
We have examined the necessity for inactivation of Pax3 during neural crest differentiation. Our knockin strategy to maintain expression of Pax3 in Pax3-expressing neural crest cells beyond the time at which endogenous expression would have normally abated has revealed what we believe is a novel role for Pax3 in craniofacial skeletogenesis and osteoblast differentiation and maturation. During early patterning, undifferentiated cranial crest must resist differentiation cues in order to migrate and proliferate appropriately. Likewise, adult stem cells must employ mechanisms to remain undifferentiated until appropriate environmental signals are recognized. Our results suggest that 1 mechanism by which neural crest cells can resist osteogenic differentiation is by secretion of the soluble BMP inhibitor Sostdc1. Thus, our data show that persistent Pax3 expression causes cranioskeletal defects including cleft or shortened palates that result in neonatal lethality. Persistent expression of Sostdc1 results in diminished BMP responsiveness, as seen by decreased phosphorylated Smad1/5/8 in the palatal mesenchyme. This is associated with diminished osteogenesis and decreased expression of Runx2, a "master regulator" of osteoblast commitment and maturation that is required for bone mineralization (36, 38, 41) .
Cleft palate is a common birth defect that occurs in 0.1%-0.2% of live births worldwide (49) . The formation of the secondary palate requires a series of complex and highly coordinated events, beginning with the elongation of the palatal shelves at about E11 and continuing to the elevation and fusion of these shelves above the tongue by E14.5, separating the oral and nasal cavities. Mineralization of the palate occurs via intramembranous ossification in which condensations of mesenchymal cells directly differentiate into osteoblasts (46, 50) . Several factors have been implicated in palatogenesis including sonic hedgehog, FGFs, Snail, TGF-β, and BMP receptors, although these reports do not provide mechanistic explanations for failure of palatal shelves to lift (49, 51, 52) . However, we did not observe obvious alterations in the expression of these genes (Supplemental Figures 4-6 and data not shown). Although subtle changes in expression that are below the detection threshold of in situ hybridization cannot be ruled out, QPCR analysis of BMPR-1a, -1b, and -2 did not reveal any difference in transcript levels.
Persistent expression of Pax3 from the Rosa26 locus under the control of the Pax3Cre knockin recapitulates proper spatial expression domains for Pax3 (27) , and expression levels appeared similar to endogenous levels. Consistent with this, expression from the Rosa26 locus is sufficient to largely rescue embryonic development in mice otherwise null for Pax3. Cleft palate was evident when Pax3 was persistently expressed in mice homozygous for the R26Pax3 allele, regardless of whether 0, 1, or 2 alleles of endogenous Pax3 were present. Also, palate defects were not evident until time points when endogenous Pax3 expression was normally decaying. These observations indicate that the defects in palatogenesis that we describe are due to persistent Pax3 expression rather than to altered levels of Pax3 in cranial crest during early time points when Pax3 is normally expressed. Further, our analyses of the Pax3-expressing cells in the developing palatal shelves indicate that migration and survival of these cells are not affected and thus not likely to be a cause of the defects in palatal development.
We hypothesize that expression of Pax3 may function in part to retain mesenchymal progenitor cells in an undifferentiated state, and abatement of Pax3 expression is necessary for normal progression of osteoblast differentiation. Upregulation of the BMP-inhibitor Sostdc1 resulting from direct transcriptional regulation by Pax3 may result in a delay or block in osteoblastogenesis by blocking BMP and Smad signaling-induced commitment and/or differentiation by mechanisms that include inhibition of Runx2 expression. This model is consistent with the role of Pax3 in melanocyte precursors, where it functions to activate expression of Mitf, while simultaneously inhibiting Mitf from activating downstream genes and melanocyte differentiation (9) . Thus, adult melanocyte stem cells that continue to express Pax3 are prevented from melanocytic differentiation. In cranial crest, Pax3 is likely to regulate Sostdc1 expression by working in concert with other transcription factors, as we failed to detect significant modulation of Sostdc1 reporter constructs by Pax3 in luciferase transcription assays (data not shown). Although the present work focuses on the osteogenic defect in the developing palate, additional defects in neural crest-derived bones were observed. The alisphenoid, pterygoid processes of the basisphenoid and tympanic bones, which were all affected, are derived from neural crest (30) (31) (32) (33) , suggesting a broad effect of persistent Pax3 expression on neural crest-derived osteogenic tissues.
Surprisingly, we did not observe gross defects in many neural crest-derived tissues in mice with persistent expression of Pax3. For example, the outflow tract of the heart and the smooth muscle layer of the aortic arch develop properly despite maintained Pax3 expression ( Figure 1D ). However, defects in adult tissues derived from Pax3 lineage precursors could not be evaluated due to neonatal lethality of the mice persistently expressing Pax3. Several factors may account for the lack of additional embryonic defects. It is possible that persistent Pax3 activity is well tolerated in some tissues. Also, it is likely that Pax3 activity is regulated by multiple mechanisms (ref. 53 and our unpublished observations) in addition to transcriptional regulation and that Pax3 protein expression does not directly reflect transcriptional activity. Absence of required cofactors or the presence of inhibitory factors might result in a dampening of the functional activity of persistent Pax3 expression in some tissues. In melanoblasts, for example, active Wnt signaling appears to result in displacement of Pax3 from some enhancers (9) . In the case of skeletal muscle development, although Pax3 Cre/+ , R26 Pax3/Pax3 pups have normal limb musculature at birth, neonatal lethality precludes an examination of possible adult muscle phenotypes and satellite cell function during maintenance and regeneration of skeletal muscle. Although Pax3 Cre/+ , R26 Pax3/+ heterozygous adults do not have an obvious defect in muscle growth and maintenance (data not shown), it is clear that 1 copy of the R26Pax3 allele is not sufficient to produce a dramatic phenotype.
In summary, we have utilized an in vivo genetic approach to address the question of whether inactivation of a developmentally critical transcription factor is necessary for proper fate determination and tissue development. Our results suggest that temporal regulation of Pax3 expression during embryogenesis is critical for cranial neural crest development and suggest that both activation and inactivation of transcriptional regulators should be the focus of future analysis.
Methods
Knockin mouse generation and genotyping. The Rosa26-Pax3 knockin construct was generated by inserting the Pax3 cDNA (GenBank accession number NM_008781) from pCMV-Pax3dhfr (20) into pBigT (41) . Subsequent cloning steps to produce the targeting vector and targeted R1 ES cells were essentially as described (41) . Rosa26-Pax3 mice were genotyped in a duplex PCR reaction with the following primers: R26F2, 5′-AAAGTCGCTCTGAGTT-GTTAT-3′; R523, 5′-GGAGCGGGAGAAATGGATATG-3′; and R1295, 5′-GCGAAGAGTTTGTCCTCAACC-3′, which produced a wild-type band of 584 bp and a mutant band of 250 bp. Pax3 Cre/+ mice were genotyped as previously described (27) . All animal studies were approved by the University of Pennsylvania Institutional Animal Care and Use Committee.
Immunoblot. Total cell lysates, nuclear extracts, or whole-embryo lysates were prepared and run on 4%-12% SDS-PAGE gels. Protein concentration was measured by BCA assay (Pierce Biotechnology) and equal amounts of total protein were loaded. Protein gels were transferred onto nitrocellulose membranes and blotted with monoclonal Pax3 antibody (University of Iowa Developmental Studies Hybridoma Bank).
Immunohistochemistry and in situ hybridization. Immunohistochemistry was performed using monoclonal Pax3 antibody, polyclonal PEBP2aA (M-70) antibody (Santa Cruz Biotechnology Inc.) against Runx2, and pSmad1/5/8 antibody no. 9511 (Cell Signaling Technology). Runx2 in situ hybridization (54) was performed using a 300-bp EcoR1/XbaI fragment of the Runx2 5′UTR (36) . Intensities of control and experimental images were always adjusted to the same degree using Adobe Photoshop CS3.
Skeleton and primary palate culture staining. Alizarin red/Alcian blue staining was performed on newborn pups after removing skin and internal organs. The carcasses were fixed in 90% ethanol, then placed in 0.1 mg/ml Alcian blue 8GX in 20% (v/v) glacial acetic acid/80% (v/v) ethanol for 7 days. After rehydration, the samples were placed in fresh 1% (w/v) potassium hydroxide (KOH) for 24 hours. After the samples became translucent, they were placed in 0.2 (w/v) mg/ml alizarin red S in freshly prepared 1% KOH for 2-3 days. The stained skeletons were further cleared in fresh 1% (w/v) KOH and then dehydrated in glycerol for imaging and storage. Goldner's trichrome staining was performed for 5 minutes in ponceau/acid fuchsin ; Sigma-Aldrich], 2 ml glacial acetic acid, to 1 l with distilled water) with acetic acid rinses in between each step. Von Kossa and ALP staining were performed as described (55) .
Primary palate cultures. Paired palatal shelves were dissected from E14.5 embryos and placed in cold PBS with 2% Fungizone (Invitrogen) in individual wells of a 24-well dish. The following steps were performed under sterile conditions in a tissue culture hood: the PBS was aspirated and replaced with 750 μl of 0.25% trypsin (Invitrogen) and incubated at 4°C for 10 minutes followed by 37°C for 5 minutes. Palates were then dissociated by trituration in 0.25% trypsin with a 1-ml pipette. Trypsinization was halted by addition of 80 μl FBS, and the dissociated cells were seeded in 1 well of a 6-well dish for each embryo. Cells were cultured in α-MEM, 10% FBS, and 1% Fungizone (Invitrogen) for 2-3 days until nearly confluent and then expanded into a 10-cm dish. Cells were seeded for Von Kossa and ALP staining in a 12-well dish at 100,000 cells/well in α-MEM, 10% FBS, and 1% penicillin/streptomycin. At confluence, cells were treated with 100 ng/ml BMP-2 (R&D Systems). For BMP treatment, cells were seeded in 6-cm culture dishes at approximately 400,000 cells/dish and grown until confluent, about 2-3 days. At confluence, cells were starved overnight in 1.5 ml total volume starvation medium: Opti-MEM (Invitrogen), 1% FBS, and 1% penicillin/streptomycin. The next day, conditioned medium was collected and spun at 2000 g for 4 minutes to remove dead cells and debris. BMP was added at the stated concentrations, and then the treated conditioned medium was replaced on the cells. Cells were incubated with BMPtreated conditioned medium for 30 minutes at 37°C, after which nuclear extracts were prepared.
Sostdc1-conditioned medium preparation. 293T cells were seeded in 10-cm dishes and transfected overnight with 5 μg of myc-tagged Sostdc1 or control vector using FuGENE 6 reagent as described (Roche Applied Science). The day after transfection, medium was replaced with 5 ml of Opti-MEM (Invitrogen), 1% FBS, and 1% penicillin/streptomycin. Conditioned medium was collected 48 and 72 hours after transfection, and cellular debris was pelleted at 2000 g for 4 minutes prior to use.
QPCR. First-strand cDNA was prepared using either Superscript Reverse Transcriptase III (Invitrogen) or High Capacity cDNA Synthesis (Applied Biosystems) according to the product guides. Runx2 (Mm0501578_m1) was assayed with TaqMan probes and master mixes (Applied Biosystems) normalized to Gapdh (Mm9999915_g1). Sostdc1 was assayed using SYBR green master mixes (Applied Biosystems) and the following primer set: Sostdc1F: 5′-CCATTGCTCTTTCCTCACTT-3′, Sostdc1R: 5′-GATGGAAACTACAG-GATGCC 3′. SYBR green assays were normalized to Gapdh using the following primers: GapdhF: 5′-TGTCTTCACCACCATGGAGAAGG-3′, GapdhR: 5′-GTGGATGCAGGGATGATGTTCTG-3′. Assays were performed in triplicate, and the averages of at least 3 independent experiments are shown. Statistical analysis was performed using 1-tailed Student's t test relative to the control sample for each condition. P < 0.5 was considered significant.
Microarray analysis. Microarray analysis was performed on 8 pairs of dissected palatal shelves from E14.5 Pax3 Cre/+ , R26 +/+ and Pax3 Cre/+ , R26 Pax3/Pax3 embryos collected from 2 litters. Palates were homogenized in 1 ml of Trizol (Invitrogen), and RNA was prepared using RNeasy columns (QIA-GEN) and eluted in 30 μl RNase-free water. Purified RNA was submitted to the Penn Microarray Facility (http://www.med.upenn.edu/microarr) for analysis on Mouse Affymetrix MOE430 v2.0 chips. Statistical analyses of gene expression were performed using BioConductor open-source software packages in R (http://www.bioconductor.org). Cells from 8 mice spread across 2 litters were used, and fluorescence intensity measures were normalized by robust multiarray analysis (56) . To identify differentially expressed transcripts we used the limma package (57), which adopts a Bayesian approach. The identification of differentially expressed transcripts controlled for effects of variations between mouse litters. R-scripts for these analyses are available in Supplemental Methods, and R-script output is provided in Supplemental Table 2 . Microarray data will be available at GEO Profiles, NCBI.
Genome sequence extraction. All Affymetrix spots with nominally significant differential expression (P < 0.01) were ranked in descending order according to their expression fold-change (wild type versus mutated). The top 50 probes were selected for subsequent analysis. The Affymetrix IDs for these 50 spots were then converted into Ensembl IDs (www.ensembl.org), and 5000 bp sequences upstream and downstream of their associated mouse genes were extracted using the BioMart database (www.ensembl.org). We retained only those genes with orthologs in the human genome, of which there were 30. Upstream and downstream sequences from the coding region of the human orthologs were also extracted.
Motif-finding analysis. Motif-finding analysis was conducted using the PhyME 1.2 package (http://edsc.rockefeller.edu/cgi-bin/phyme/ download.pl). Parameter settings were as follows: 2 species, 30 sequences,
